StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.
Separately, Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.
Get Our Latest Stock Analysis on Moleculin Biotech
Moleculin Biotech Price Performance
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- How to Capture the Benefits of Dividend Increases
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Why Are These Companies Considered Blue Chips?
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- The 3 Best Fintech Stocks to Buy Now
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
